Alimera Sciences Inc. (ALIM)

1.07
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 1.07
Open 1.09
Day Low/High 1.07 / 1.10
52 Wk Low/High 0.72 / 1.34
Volume 21.23K
Avg Volume 86.00K
Exchange NASDAQ
Shares Outstanding 70.08M
Market Cap 75.69M
EPS -0.30
P/E Ratio 7.20
Div & Yield N.A. (N.A)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARES, HPR, IDCC, INS, IOR, RXN, TCI, TEO, TSU, VST, WMK Downgrades: ALIM, BBGI, CAG, CBM, CNDT, DEI, FNJN, NNBR, PENN Initiations: LOMA, NVMM Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AES, ALIM, APPS, EXAS, INVH, LBRDA, LBRDK, LLY, TLK Downgrades: CTT, DRH, HA, MTDR, ORIT, RNG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Alimera Sciences Announces Nine Clinical Presentations And A Sponsored Symposium At 18th EURETINA Congress

Alimera Sciences Announces Nine Clinical Presentations And A Sponsored Symposium At 18th EURETINA Congress

"CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the Treatment of Persistent or Recurrent DME" Symposium to be held on Friday

Alimera Sciences Announces Three Podium Presentations For ILUVIEN® To Be Presented At 2018 Retina Society's Annual Meeting

Alimera Sciences Announces Three Podium Presentations For ILUVIEN® To Be Presented At 2018 Retina Society's Annual Meeting

ATLANTA, Sept. 13, 2018 /PRNewswire/ -- Alimera Sciences, Inc.

Alimera Sciences Announces Exchange Of Series B Preferred Stock For Newly Issued Series C Preferred Stock

Alimera Sciences Announces Exchange Of Series B Preferred Stock For Newly Issued Series C Preferred Stock

ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc.

Alimera Sciences To Present At The 20th Annual HC Wainwright Global Investment Conference

Alimera Sciences To Present At The 20th Annual HC Wainwright Global Investment Conference

ATLANTA, Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive...

Alimera Sciences To Present At The Annual B. Riley Healthcare Conference

Alimera Sciences To Present At The Annual B. Riley Healthcare Conference

ATLANTA, Aug. 28, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive...

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital

Elimination of liquidity covenants frees working capital to fuel company growth

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

Alimera Sciences Announces 9 Clinical Presentations And A Sponsored Symposium At 17th Euretina Congress

20 electronic posters available for review as well

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Alimera Sciences Signs Agreement For Exclusive Distributor Of ILUVIEN® In France

Horus Pharma S.A.S. to also serve as agent in price negotiations with French Regulatory Authorities

TheStreet Quant Rating: D (Sell)